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Research
AbstrACt
Objective To assess the cost-effectiveness of an 
enhanced transtheoretical model of behaviour change in 
conjunction with physiotherapy compared with standard 
care (physiotherapy) in patients with chronic lower back 
pain (CLBP).
Design Cost-utility and cost-effectiveness analyses 
alongside a multicentre controlled trial from a healthcare 
perspective with a 1-year time horizon.
setting The trial was conducted in eight centres within 
the Sharon district in Israel.
Participants 220 participants aged between 25 and 55 
years who suffered from CLBP for a minimum of 3 months 
were recruited.
Interventions The intervention used a model of behaviour 
change that sought to increase the adherence and 
implementation of physical activity in conjunction with 
physiotherapy. The control arm received standard care in 
the form of physiotherapy.
Primary and secondary measures The primary outcome 
was the incremental cost per quality-adjusted life year 
(QALY) of the intervention arm compared with standard 
care. The secondary outcome was the incremental cost 
per Roland-Morris Disability Questionnaire point.
results The cost per QALY point estimate was 10 645 
New Israeli shekels (NIS) (£1737.11). There was an 
88% chance the intervention was cost-effective at 
NIS50 000 per QALY threshold. Excluding training costs, 
the intervention dominated the control arm, resulting in 
fewer physiotherapy and physician visits while improving 
outcomes.
Conclusions The enhanced transtheoretical model 
intervention appears to be a very cost-effective 
intervention leading to improved outcomes for low cost. 
Given limitations within this study, there is justification 
for examining the intervention within a larger, long-term 
randomised controlled trial.
trial registration number NCT01631344; Pre-results.
IntrODuCtIOn  
Lower back pain is the number one cause of 
daily disability worldwide.1 It remains highly 
prevalent and difficult to treat.2 Increased 
physical activity is recommended as the 
most promising and effective approach to 
treating patients with chronic lower back 
pain (CLBP).3 Evidence suggests that phys-
ical activity is effective in improving function, 
preventing further pain and improving return 
to work outcomes.4 5 However, adherence to 
advice to start and maintain higher levels of 
physical activity is problematic,6 7 with many 
people failing to continue to exercise in the 
long term.7 Criticisms of existing interven-
tion suggest the need for theory-driven inter-
ventions that focus on the key obstacles to 
long-term rehabilitation.7 An enhanced trans-
theoretical model intervention (ETMI) of 
behaviour change was developed to address 
this.8 ETMI seeks to increase the adherence 
and implementation of physical activity by 
harnessing theory-informed counselling 
based on behaviour change principles to 
overcome barriers to exercise. In line with 
strengths and limitations of this study
 ► The enhanced transtheoretical model intervention 
is a novel intervention that integrates behaviour 
change theory into physical therapy appointments.
 ► Healthcare and medication data were collected via 
routine data sources providing detailed information 
on healthcare and medication use.
 ► Generalisability to the region—recruitment methods 
reflected actual referral processes with nearly all re-
ferrals within the Sharon district being included in 
the study.
 ► Due to the recruitment method reflecting reality, se-
lection bias cannot be ruled out.
 ► No Israel-specific SF-6D algorithm exists and thus 
quality-adjusted life years will differ if preferences 
differ between countries.
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theory, ETMI matches patients’ readiness to change with 
an appropriate consultation style from the practitioner. 
Additionally, it aims to tackle fear of movement, while 
enhancing reassurance and education about CLBP.
In the primary clinical paper,8 ETMI was found, in an 
Israeli study, to be more effective than usual physiotherapy 
as assessed with the Roland-Morris Disability Question-
naire (RMDQ)9 as a primary outcome (2.7 point difference 
in mean change from baseline). In addition, it performed 
better on the physical scale of the SF-12 questionnaire,10 
worst and average levels of pain, and self-report of levels 
of physical activity. As well as demonstrating effectiveness, 
it is important to consider the cost-effectiveness of imple-
menting new interventions. In Israel, interventions that have 
a cost per quality-adjusted life year (QALY) less than 50 000 
New Israeli shekels (NIS) tend to be approved by the Public 
Committee and can therefore be considered cost-effec-
tive.11 In the UK, the National Institute for Health and Care 
Excellence (NICE) uses the threshold of £20 000–£30 000 
per QALY12 to assess cost-effectiveness. This research takes 
place within the Israeli context. In this paper we seek to 
answer the question of whether ETMI is more cost-effective 
than usual care for young patients with CLBP.
MethODs
The economic analysis is characterised as a within-trial cost-
utility analysis examining the incremental cost per QALY 
associated with introducing the intervention. The ETMI 
study was a multicentred, pragmatic controlled trial of 
patients with CLBP. It is described in detail elsewhere.8 The 
trial ran between February 2011 and July 2012. Informed 
consent was mandatory for inclusion within the trial. 
The trial was registered pre—results on  ClinicalTrials. gov 
(NCT01631344). This analysis uses a 1-year time horizon 
(reflecting the clinical paper); hence, costs and outcomes 
were not discounted. Prices are presented in 2012 terms 
(the year the trial concluded). Costs are presented in NIS, 
with Great Britain pounds (GBP) in parentheses. The 
exchange rate from mid-2012 is used to convert NIS to GBP 
(NIS6.128=£1).
Population
The trial focused on people aged between 25 and 55 years 
with CLBP (as defined by a duration of over 3 months) 
who were referred to the Maccabi Health Services physical 
therapy clinics within the Sharon district. Older patients 
were not considered as there is evidence that a transthe-
oretical approach to increase compliance in older popu-
lations is not effective.13 All participants were required to 
speak Hebrew fluently. Patients with the following contra-
indications were excluded: rheumatic diseases, tumours, 
fractures, fibromyalgia, previous spinal surgery, pregnancy 
and post-car (or work) accident pain.
recruitment and arm allocation
Eight participating centres were recruited. Across 
the eight centres, 11 physiotherapists administered 
the intervention, while 23 provided normal care. All 
physios had in excess of 4 years of experience. All refer-
rals for physiotherapy from general practice or ortho-
paedic secondary care within the district were allocated 
by an independent party to the nearest physiotherapist 
according to geographical location without knowledge 
of whether the physiotherapist was within the trial. 
Although not randomised, the allocation of partici-
pants was not under the influence of the study team. 
On arriving for treatment, eligibility was assessed and 
eligible participants were provided with information 
about the trial. Those who did not consent were not 
included in the study and proceeded to receive treat-
ment as usual.
Interventions
The two arms of the trial can be characterised as follows:
1. Usual care (control)—The usual care group received 
standard physical therapy treatment, and this could 
include mobilisation, manipulation, back exercis-
es, postural training, attending back school, electri-
cal stimulation, short wave diathermy, cooling and 
stretching.
2. With the exception of back exercise, the intervention 
did not use any of the methods associated within the 
usual care arm. The main aim of the intervention 
was to facilitate participation in a chosen recreation-
al physical activity through matching and supporting 
the patient’s cognitive readiness to change, and so re-
ducing known barriers to physical activity such as low 
motivation, low self-efficacy and fear of movement. A 
semistandardised protocol was used for the interven-
tion (see online supplementary materials); a full ex-
position of the enhanced intervention can be found 
in Ben-Ami et al.8
resource use and costs
The costing perspective adopted for this study was a 
healthcare perspective; wider societal costs were not 
considered. The healthcare perspective included the cost 
of training staff to deliver the intervention, the cost of 
delivering the intervention (including the time and mate-
rials used) and healthcare costs. Information on health-
care use was captured primarily through the computerised 
medical records that are available through the Maccabi 
Healthcare Services. These records were used to extract 
information on physiotherapist appointments, general 
practitioner appointments and all pain and inflammation 
medication; this includes over-the-counter purchases. 
No data on hospitalisation were captured. Training costs 
were recorded by the trial team. Unit costs were obtained 
from the Ministry of Health.14 15 Resource use was retro-
spectively collected for the 3 months prior to the start 
of the trial to assess baseline resource use, and for the 
12 months of follow-up. Consequently, information was 
available for all physiotherapy appointments, all doctor 
appointments, all pain and inflammation medication, 
and the costs associated with setting up and delivering 
the intervention.
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Outcomes
The primary outcome for the economic evaluation was 
incremental cost per QALYs as recommended.16 QALYs 
are a unit of outcome that combines both quantity and 
quality of life into a single metric. QALYs have been widely 
adopted in many countries around the world (eg, NICE 
in the UK12). To obtain utility values for QALY calcula-
tion within this study, the 12-Item Short Form Survey 
(SF-12) was included at baseline and both follow-ups (3 
months and 12 months). The SF-12 is a generic health-re-
lated quality of life questionnaire examining 12 domains 
of health.10 Algorithms exist to convert SF-12 scores into 
Short Form Six Dimension (SF-6D) utility values.17–19 As 
version 1 (US) SF-12 instrument was used, the appropriate 
algorithm provided by the University of Sheffield was 
used to calculate utility values.17–19 From baseline through 
the follow-ups, these health utilities were combined with 
length of time information to calculate QALYs. QALYs 
were calculated using the trapezium rule, which calcu-
lates the area under the curve.20 The second outcome 
considered was the RMDQ, a common and well-validated 
back pain-specific measure9 21 22 suitable to this setting 
which formed the primary outcome in the clinical eval-
uation of the intervention.8 The RMDQ is designed to 
assess disability caused by lower back pain and contains 
24 statements relating to disability caused by back pain 
(eg, I can only walk short distances because of my back). 
Each answer is worth 1 point, resulting in scores between 
0 (no disability) and 24 (severely disabled).
statistical analysis
First, costs and outcomes between the two arms were 
compared in isolation. They were then combined within 
a cost-effectiveness analysis that analysed both costs and 
outcomes simultaneously. Given the hierarchical struc-
ture of the data, appropriate statistical methods were 
required.23 The primary analysis is a complete case 
analysis.
Analysis of costs and QALYs
We included relevant characteristics and baseline scores 
as covariates within a regression framework to control for 
baseline differences in characteristic or health states.24–26 
Due to the clustered nature of the data, it was neces-
sary to use analytical methods that accounted for clus-
tering.23 Multilevel models were adopted allowing for 
random effects at the physiotherapist and centre level. 
Finally, the skewness of the data can affect the method 
of analysis used. Given the skewed cost data collected in 
the trial, it was necessary to adopt a method that could 
handle non-parametric data. Generalised linear models27 
were therefore implemented using a gamma family and 
identity link function following tests (data visualisations, 
modified Park test and ‘linktest’) to optimise model fit. 
Thus, the final model was a multilevel generalised linear 
model controlling for baseline characteristics (including 
age, gender, body mass index (BMI), health state and 
years of education). This simultaneously addressed the 
three specified issues relevant to the data. This was imple-
mented within Stata V.1428 using the ‘meglm’ code.
examining cost-effectiveness
An incremental cost-effectiveness ratio (ICER) can be 
calculated by dividing the incremental costs by incre-
mental QALYs. A cost per QALY approach, however, does 
not reflect that costs and outcomes may be correlated and 
does not characterise the uncertainty that is present.26 29 
To address this, we used the net benefit approach, which 
combines costs and QALYs into a single metric of net 
benefit.30 The net benefit approach multiplies QALYs 
with the willingness to pay (WTP) for those QALYs by the 
decision maker, and then subtracts the costs.30 This was 
done for a range of WTP values. To control for clustering, 
a hierarchical approach was necessary.31 A multilevel 
regression framework was therefore used for each WTP 
level to assess the cost-effectiveness while also controlling 
for baseline imbalances and clustering. Given the para-
metric nature of net benefits, a generalised linear model 
was not required; hence, the ‘mixed’ Stata command was 
used. Within the model, for any WTP, if the intervention 
coefficient (the incremental net benefit) was greater 
than 0, then the intervention was deemed cost-effec-
tive at that WTP. Using data from the output of the net 
benefit regressions, cost-effectiveness acceptability curves 
(CEACs) were generated to characterise the uncertainty 
in decision making at each level of WTP.25 30
secondary analysis
Cost per RMDQ point was examined as a secondary anal-
ysis. The analysis methods outlined above were followed; 
however, the outcome of interest was ‘difference in 
RMDQ’ score rather than QALYs.
sensitivity analyses
We ran two further sensitivity analyses:
1. Multiple imputation in Stata for missing data: A 
fixed-effect approach for multiple imputation was 
used to address the potential impact of missing data. 
Each arm was imputed separately and 10 imputed 
data sets were created. We combined data for analy-
sis using Rubin’s rules.32 The same multilevel models 
previously outlined were then used to analyse the mul-
tiply imputed data and to examine cost-effectiveness. 
A CEAC was generated from the imputed data.
2. Real-world running costs: Clinician training is a one-
off cost, and once up and running there would be 
no further costs related to training. Thus the same 
clinicians could conduct the intervention on fur-
ther cohorts of participants without further training. 
This sensitivity analysis therefore excluded training 
costs and only considered the running costs of the 
intervention.
resuLts
Baseline characteristics for the two arms of the trial 
are presented in table 1. Data were collected for 220 
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participants, of which 109 were in the intervention arm. 
Arms were well balanced in terms of age, BMI and educa-
tion. Although not statistically significant, there were 
notable differences in gender and baseline health utility 
(0.62 vs 0.66). This is reflected in the baseline resource 
use and baseline cost data, with the control arm using 
more healthcare at baseline than the intervention arm. 
Thus, it was necessary to control for baseline variables 
within the economic analysis.
Both arms saw improvements in both utility and RMDQ 
over time. The mean utility scores in the control arm 
increased from 0.62 to 0.74, while the control arm saw 
improvements from 0.66 to 0.79. This suggests that both 
interventions were beneficial to the patients. For the 
RMDQ, the control arm improved from 10.24 down to 
5.97, while the intervention arm saw improvement from 
9.95 to 3.27 (table 2).
Intervention and healthcare resource use and costs are 
shown in table 3. The biggest drivers of cost related to the 
intervention itself were training costs to ensure the inter-
vention was implemented correctly. In terms of interven-
tion materials, the intervention is very cheap, owing to 
the fact that the only extra materials are instructional 
postcards for intervention participants. The primary 
Table 2 Outcome data
Control Intervention
Baseline 3 months 12 months Baseline 3 months 12 months
SF-6D utility by arm
  Observations 107 98 95 108 100 94
  Mean utility 0.62 0.73 0.74 0.66 0.77 0.79
  SD 0.13 0.14 0.15 0.14 0.14 0.11
  Min 0.37 0.36 0.37 0.38 0.38 0.42
  Max 0.94 1 1 1 1 1
RMDQ score by arm
  Observations 111 98 95 109 100 94
  Mean RMDQ score 10.24 6.83 5.97 9.95 4.73 3.27
  SD 5.18 5.91 5.51 4.95 4.66 4.45
  Min 1 0 0 1 0 0
  Max 21 23 21 21 23 22
RMDQ, Roland-Morris Disability Questionnaire.
Table 1 Baseline data
Control arm Intervention arm
n Mean SD n Mean SD
Baseline characteristics
  Age 111 42.31 7.15 109 42.37 7.55 
  BMI 110 26.11 5.02 108 26.13 4.84
  Years of education 110 14.93 2.68 108 14.45 2.68
  Gender: male 47 NA NA 54 NA NA
  Gender: female 64 NA NA 55 NA NA
Baseline health outcomes
  Baseline SF-6D 107 0.62 0.13 108 0.66 0.14
  RMDQ score 111 10.24 5.18 109 9.95 4.95
Baseline resource use
  Baseline number of medications 111 1.43 1.44 107 1.37 1.50
  Baseline number of doctor visits 111 1.58 1.30 107 1.55 1.29
Baseline costs
  Baseline medication costs (NIS) 111 49.83 51.45 106 45.41 53.25
  Baseline doctor appointment costs (NIS) 111 197.07 162.15 107 193.93 161.28
BMI, body mass index; NA, not applicable; NIS, New Israeli shekel; RMDQ, Roland-Morris Disability Questionnaire. 
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cost of the intervention is the physiotherapy care itself; 
due to the nature of the intervention, it is impossible to 
disentangle where the ETMI care ends and other phys-
iotherapy appointments begin, thus intervention costs 
related to ETMI are captured within the healthcare costs. 
There were lower levels of resource in terms of medica-
tion, doctor visits and physiotherapist appointments for 
the intervention arm compared with the control arm. 
The most notable difference relates to physiotherapy 
appointments used: the control arm had on average 
5.11 appointments at a cost of NIS643.62 (£105.03) per 
patient compared with just 3.62 at a cost of NIS455.72 
(£74.36) per patient for the intervention arm. The base-
line and centre-adjusted cost difference specifically for 
physiotherapy appointments demonstrated a saving of 
NIS191.79 (95% CI 289.51 to 94.07), and this is statisti-
cally significant (P=0.00).
The intervention arm was associated with an extra 0.02 
QALYs (95% CI −0.01 to 0.05) per intervention partici-
pant compared with the control arm. Reflecting the QALY 
results, the condition-specific RMDQ demonstrated a 
reduction in RMDQ score of 2.67 (95% CI −4.03 to –1.31) 
in comparison with the control arm. Incremental costs 
were higher for the intervention arm, with a cost differ-
ence of NIS230.35 (£37.59) per participant (95% CI 
NIS85.26 to NIS375.44). Thus, costs were higher for the 
intervention arm, but outcomes were better (table 4).
The net benefit (NB) curve intersects the x-axis at 
approximately NIS10 000 (£1631.85) (figure 1). This 
point reflects where NB is equal to 0 and thus approxi-
mates the cost per QALY. The lower CI never crosses 0. 
This suggests that regardless of WTP, there will always be 
some uncertainty surrounding the result. This reflects 
the modest intervention effects and the increased costs 
related to the intervention. The CEAC in figure 2 shows 
the probability at different levels of WTP that the inter-
vention is more cost-effective than the control. At very low 
levels of WTP, the control arm is likely the more cost-ef-
fective option, with the intervention just having a 27% 
chance of being the more cost-effective option at a WTP 
Table 3 Resource use and costs
Intervention costs (cluster level)
Component Details
Resource 
used Unit cost (NIS)
Total cost 
(NIS)
Cost per intervention 
physiotherapist (NIS)
Cost per 
intervention 
patient (NIS)
Physiotherapist 
training
12 trainees attended: 
2 days
192 hours 126 per 30 min 48 384 4398.55 443.89
Trainers’ time: 2 days 16 hours 126 per 30 min 2016 183.27 18.50
Materials Postcards for 
physiotherapists
13 per 
physio
650 total 650 59.09 5.96
Total: 51 050 4640.91 468.35
Healthcare resource use and cost data (unadjusted)
Control arm (missing n=0) Intervention arm (missing n=2)
n Mean SD Min Max n Mean SD Min Max
Medication used 111 1.60 2.68 0 22 107 1.21 2.11 0 17
Doctor visits 111 1.49 2.47 0 12 107 1.02 1.97 0 17
Physio appointments 111 5.11 3.44 1 18 107 3.62 1.97 1 12
Medication costs (NIS) 111 48.38 80.97 0 595.88 107 39.49 76.50 0 654.02
Doctor costs (NIS) 111 185.81 308.90 0 1500 107 127.34 245.83 0 2125
Physio costs (NIS) 111 643.62 432.94 126 2268 107 455.72 248.19 126 1512
NIS, New Israeli shekel.
Table 4 Incremental analysis: intervention versus control—fully adjusted for baseline, covariates and clustering
Mean difference SE z P>z  95% CI 95% CI
QALYs 0.02 0.01 1.45 0.15 −0.01 0.05
Change from baseline 
RMDQ
−2.67 0.69 −3.85 0.00 −4.03 −1.31
Cost (NIS) NIS230.35 74.03 3.11 0.002 85.26 375.44
Cost per QALY NIS10 645.12
Cost per RMDQ point NIS86.27
NIS, New Israeli shekel; QALY, quality-adjusted life year; RMDQ, Roland-Morris Disability Questionnaire. 
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of NIS5000 (£815.93). As WTP for QALYs rises, the prob-
ability of the intervention quickly increases. At a WTP of 
NIS20 000 (£3263.71) per QALY, there is a 78% chance 
that the intervention is the more cost-effective option. 
This rises to 88% by a WTP of NIS50 000 (£8159.27), 
before stabilising at about 89% for higher WTP levels.
secondary analysis
The adjusted mean change in RMDQ score between the 
two arms was −2.67 (P=0.000). The CEAC analysis associ-
ated with the RMDQ scores found that even at a very low 
WTP of NIS100 (£16.32) per RMDQ point, there is a 81% 
chance the intervention is the more cost-effective option. 
By NIS200 (£32.64), there is a 99% chance the interven-
tion is the more cost-effective option.
sensitivity analyses
The first sensitivity analysis addresses the issue of missing 
data. Attrition was relatively low with just 14% of SF-6D 
scores being missing at the final follow-up. Multiple impu-
tation of missing data has limited impacts on the results. 
At a WTP of NIS50 000 (£8159.27) per QALY, there is an 
85% chance that the intervention is the more cost-effec-
tive, only 3% less than the complete case analysis.
The second sensitivity analysis considers the real-world 
running costs: excluding all costs related to training. 
In this scenario the intervention is actually cost-saving, 
saving NIS−252.61 (95% CI −381.92 to 123.30) (£41.86) 
per patient. In this sensitivity analysis the intervention 
dominates the control arm: it is associated with lower 
costs and better outcomes.
DIsCussIOn
This paper has reported the first cost-effectiveness analysis 
of an ETMI aiming to increase recreational physical activity 
in patients with chronic low back pain compared with phys-
iotherapy usual care. Echoing the main study findings,8 
both trial arms improved; however, the intervention arm 
was associated with better outcomes compared with the 
usual care arms as measured by the RMDQ and QALYs. 
This suggests ETMI may be useful in reducing CLBP, but 
at what cost? In the 12 months following the intervention, 
doctor and physiotherapy appointments, as well as medica-
tion use, were all comparatively reduced in the intervention 
arm. Training costs however outweighed these cost savings. 
This biggest cost driver was training costs for delivery of the 
intervention. The point estimate of the ICER was NIS10 645 
(£1737.11) per QALY. No explicit cost per QALY threshold 
exists in Israel; it however has been reported that interven-
tions with a cost per QALY less than NIS50 000 (£8159.27) 
tend to be approved by the Public Committee.11 Thus, 
with a cost per QALY of NIS10 645 (£1737.11), the ETMI 
represents good value for money and has a very high proba-
bility (88%) of being cost-effective at the implied threshold. 
Overall our results were robust to sensitivity analyses, with 
multiple imputation for missing data having little impact 
on key results.
Our primary analysis is very conservative as it assumes all 
of the training costs are allocated to the limited number 
of people treated within the trial. If implemented in prac-
tice each trained physiotherapist will treat many more 
people than just those included in the study. Indeed, it 
could be argued that it is inappropriate to include any 
training costs in the model as these will be met else-
where as part of the normal overall running costs of the 
service. When considering only the ongoing costs, the 
ETMI dominated usual care; that is, it was cheaper and 
more effective. Regardless of how the training costs are 
managed in the analyses, these data indicate that ETMI is 
very likely to be cost-effective when compared with usual 
care and it might even be cost-saving. This reflects the 
findings of a recent review that suggest interventions that 
combine physical and psychological treatments are more 
likely to be cost-effective for CLBP.33
There are a number of strengths and limitations associ-
ated with the methodology of the study and this analysis. 
The study is novel in integrating transtheoretical models 
of behaviour change into routine physiotherapy appoint-
ments. A key strength and limitation of the study relates 
to the method of recruitment into the study. The recruit-
ment method reflected the real-world referral process and 
nearly all referrals within one geographical district were 
included. A limitation to this method of recruitment was 
Figure 1 Net benefit by willingness to pay (New Israeli 
shekel, NIS) for quality-adjusted life years (QALYs). 
Figure 2 Cost-effectiveness acceptability curve: probability 
intervention is cost-effective at different levels of willingness 
to pay (New Israeli shekel, NIS) for quality-adjusted life years 
(QALYs).
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that participants were allocated to their nearest geographi-
cally available physical therapist (the referrer had no knowl-
edge of the physiotherapist’s allocation), and thus it cannot 
claim to be a ‘randomised’ controlled trial; we cannot rule 
out selection bias. This however should be limited by the 
fact that each treatment centre contained at least one physio 
in the intervention arm, and one in the control arm, and 
those allocating patients to physiotherapists were not aware 
of which arm each physio was in. Likewise, the sample size is 
relatively small and is potentially underpowered, increasing 
the uncertainty around results. The use of routine data 
to collect information on resource use was a strength 
allowing the collection of detailed data on medication, 
doctor visits and physiotherapist visits; however, a limita-
tion to this approach was that no information on hospital 
use was collected and key costs potentially could have been 
missed. Given the intervention arm reported less disability 
and higher utility scores, it is unlikely the inclusion of such 
costs would have changed the direction of the results. The 
Israeli Ministry of Health does not specify a preferred utility 
measure to generate QALYs.16 In this study the SF-12 was 
used to capture generic health-related quality of life data 
and QALYs were derived using the associated utility algo-
rithm.17 A limitation of this is that the study was conducted 
in Israel and no Israel-specific tariff exists, and preferences 
for health states may differ from those where the tariff orig-
inates. Furthermore, although the SF-12 is validated and 
reliable for patients with lower back pain,34 the evidence 
surrounding the SF-6D is more limited35 and future studies 
should explore the use of other utility measures. CLBP by 
definition is a chronic condition; the 1-year follow-up is 
therefore a limitation as the long-term effectiveness and 
adherence could not be thoroughly assessed. Given one of 
the prime issues with CLBP is absence from work, and a key 
goal of treatment for CLBP is to enable return to work, it is 
a limitation that no data were collected on whether return 
to work was achieved. Given the comparative improve-
ment within the intervention arm, it is not unreasonable 
to presume that ability to work would also improve in this 
arm. This implies that wider productivity gains may have 
been accrued by the intervention arm that we have failed to 
capture. The study focused on younger populations, below 
age 55, and we cannot generalise the effect to older groups. 
While the study took place in a single district, it included 
a wide variety of socioeconomic groups and represents a 
large section of the Israeli population, which has only six 
districts in total.
Future research should focus on addressing the limita-
tions within this economic evaluation by conducting a 
larger scale randomised controlled trial. To compre-
hensively address limitations, a future trial would 
incorporate the following: larger sample size; using a 
randomisation procedure to allocate patients to trial 
arms; including multiple measures of utility specific 
to the setting; examining the mechanism of change 
and long-term adherence; and collecting resource use 
information on hospitalisation and wider impacts (eg, 
employment).
COnCLusIOns
The use of ETMI was associated with fewer medical 
appointments and fewer medications being necessary. 
At the same time, outcomes were improved for patients 
who received the intervention. In summary, the findings 
within this study are very encouraging and suggest that 
ETMI is a cost-effective strategy for treating CLBP, at least 
in younger populations, with an 88% probability of being 
more cost-effective than usual care. However there are a 
range of limitations to this study, combined with a modest 
sample size (n=220), and as such this should be consid-
ered a pilot study for a large-scale, long-term randomised 
controlled trial to robustly test the effectiveness and 
cost-effectiveness of ETMI.
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